Teva receives FDA approval for generic Lovaza
JERUSALEM — Teva Pharmaceutical Industries announced that it has received approval from the Food and Drug Administration for its generic form of Lovaza (omega-3-acid ethyl esters capsules, USP) in the United States.
Lovaza is used as an adjunct to diet to reduce triglycerdide levels in adult patients, according to the FDA. Teva believes it is the first to file and plans to begin shipping immediately.
Lovaza capsules, marketed by GlaxoSmithKline, had annual sales of $1.1 billion in the United States as of December 2013, according to IMS data.
Model Marloes Horst named newest face of Maybelline New York
NEW YORK — Maybelline New York has tapped Dutch model Marloes Horst to be its newest face for the brand, joining a roster of prominent spokeswomen including Christy Turlington, Emily DiDonato and a host of others.
She will make her Maybelline New York debut in print and television advertising campaigns in April.
"Marloes embodies the Maybelline New York woman with her passion for makeup and her New York City energy and ambition," stated Jerome Bruhat, global brand president of Maybelline New York.
Horst has lit up the runway for Prada, posed for the Pirelli calendar and is a Victoria’s Secret regular. Currently, Marloes is the face for the DKNY “Be Delicious” fragrance and recently posed for the Sports Illustrated 50th Anniversary issue.
Horst has been featured on the covers of such magazines as Vogue, Harper’s Bazaar, Elle, L’Officiel and Jalouse and has been seen in advertising campaigns for Calvin Klein, Stella McCartney, Carolina Herrera, H&M, Valentino, Ralph Lauren, DKNY, Tommy Hilfiger Denim and Kenzo.
Sunovion Pharmaceuticals announces availability of Aptiom
MARLBOROUGH, Mass. — Sunovion Pharmaceuticals on Monday announced that Aptiom (eslicarbazepine acetate), a once-daily antiepileptic drug, is now available across the United States.
The drug, which received approval from the Food and Drug Administration on Nov. 8, 2013, is a prescription medicine used with other medicines to treat partial-onset seizures. The drug is available in four table strengths: 200 mg, 400 mg, 600 mg and 800 mg; it can be taken whole or crushed, with food or without.
“Epilepsy is a serious condition that not only affects the people who suffer from seizures, but also their family, caregivers and friends,” said Michael R. Sperling, M.D., professor of neurology at Thomas Jefferson University and director of the Jefferson Comprehensive Epilepsy Center in Philadelphia. “Approximately one-third of those with epilepsy still have inadequate seizure control despite treatment, so we need new therapies. Aptiom is a welcome addition to our therapeutic toolkit that may help some patients.”
Epilepsy is one of the most common neurological disorders and affects nearly 2.2 million people in the United States, the company said. Partial-onset seizures are the most prevalent type of seizure and are connected with 60% of new epilepsy diagnoses.